Table 2.
Characteristics of patients in Delta-radiomics analysis.
| Characteristics | Training set | P value | Test set | P value | |||
|---|---|---|---|---|---|---|---|
| Responders | Non-responders | Responders | Non-responders | ||||
| Age, median (P25–P75) | 63 (35–84) | 63 (44–78) | 0.61 | 61 (29–75) | 62 (36–77) | 0.99 | |
| Male | 64 (35–84) | 64 (44–78) | 61 (29–75) | 62 (36–70) | |||
| Female | 55 (43–79) | 63 (59–74) | 54 (48–64) | 59 (37–77) | |||
| Sex, No. (%) | |||||||
| Male | 60 (86.96%) | 38 (88.37%) | 0.83 | 24 (80.00%) | 12 (63.16%) | 0.19 | |
| Female | 9 (13.04%) | 5 (11.63%) | 6 (20.00%) | 7 (36.84%) | |||
| Smoking history, No. (%) | |||||||
| Non-smokers | 18 (26.09%) | 13 (30.23%) | 0.58 | 8 (26.67%) | 6 (66.67%) | 0.78 | |
| Smokers | 51 (73.91%) | 30 (69.77%) | 22 (73.33%) | 13 (44.83%) | |||
| Pathological type, No. (%) | |||||||
| Adenocarcinoma | 35 (50.72%) | 26 (60.47%) | 0.31 | 14 (46.67%) | 9 (47.37%) | 0.96 | |
| Others | 34 (49.28%) | 17 (39.53%) | 16 (53.33%) | 10 (52.63%) | |||
| Distant metastasis, No. (%) | |||||||
| Absence | 17 (24.64%) | 3 (6.98%) | 0.02* | 8 (26.67%) | 3 (15.79%) | 0.06 | |
| Presence | 52 (75.36%) | 40 (93.02%) | 22 (73.33%) | 16 (84.21%) | |||
| Treatment strategy, No. (%) | |||||||
| Monotherapy | 32 (46.38%) | 27 (62.79%) | 0.09 | 17 (56.67%) | 11 (57.89%) | 0.93 | |
| Combination therapy | 37 (53.62%) | 16 (37.21%) | 13 (43.33%) | 8 (42.11%) | |||
| Rad-score of TP1 (P25–P75) | −0.47 (−0.75, −0.34) | −0.30 (−0.45, −0.18) | <0.01* | −0.44 (−0.76, −0.32) | −0.34 (−0.48, −0.19) | 0.05 | |
| Rad-score of Delta-RFs (P25–P75) | |||||||
| Target lesions | −1.02 (−1.42, −0.57) | 0.04 (−0.53, 0.54) | <0.01* | −0.97 (−1.63, −0.65) | −0.13 (−0.65, 0.12) | <0.01* | |
| Largest target lesion | −0.87 (−1.08, −0.51) | −0.20 (−0.62, 0.30) | <0.01* | −0.86 (−1.17, −0.63) | −0.46 (−0.59, −0.22) | 0.03* | |
*P value < 0.05.